[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"g6pd-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:g6pd-deficiency":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100628966","phase-4-primaquine-for-vivax-malaria-in-g6pd-intermediate-and-deficient-cases-100628966",false,"NCT07468513","Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.","Inclusion Criteria:\n\n* • P. vivax peripheral parasitaemia (mono-infection)\n\n  * G6PD intermediate or deficient status (G6PD activity 30-\\\u003C70% or ≤30% of the adjusted male median as determined by the Standard G6PD (SDBioline, ROK))\n  * Fever (temperature ≥37.5⁰C) or history of fever in the preceding 48 hours\n  * Age ≥18 years\n  * Haemoglobin at presentation ≥8g\u002Fdl\n  * Written informed consent\n  * Living in the study area and willing to be followed for six months.\n\nExclusion Criteria:\n\n* • Danger signs or symptoms of severe malaria\n\n  * Pregnant or lactating females\n  * Regular use of drugs with haemolytic potential\n  * Known hypersensitivity to any of the study drugs.","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","A non randomized observation study that is aiming to assess the safety and efficacy of high dose primaquine (1mg\u002Fkg per day over 7 days) among patients with intermediate (30-70%) G6PD activity and the safety and efficacy of weekly primaquine among patients who are g6Pd deficient (\\\u003C30% activity)",[25,26],"Vivax Malaria","G6PD Deficiency",[28,29],"Primaquine in G6PD deficiency","Vivax malaria in G6PD deficient patients","RECRUITING","2026-03-09",{"date":33,"type":34},"2026-03-12","ACTUAL",{"date":36,"type":34},"2024-05-17",{"date":38,"type":19},"2028-12-31",{"name":40,"class":41},"Menzies School of Health Research","OTHER",4]